Tag: enzymes

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving rapid and durable disease control —

European Commission approval expands the indication of lomitapide in the European Union (EU) to include children 5 years of age and older with HoFH, an ultra-rare genetic disorder affecting LDL-cholesterol levels

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

SEOUL, South Korea, Aug. 14, 2025 (GLOBE NEWSWIRE) -- EU Good Food has officially introduced premium European kiwis and canned peaches to Korean consumers, marking an important milestone in its collaboration with the Korean market. This launch highlights the initiative’s long-term commitment to delivering high-quality, fully traceable European ingredients to Korea’s food industry and households.

Ad hoc announcement pursuant to Art. 53 LR

Growing interest in natural respiratory support draws attention to ingredient-first formulations like LungExpand Pro, blending plant extracts and nutrients often discussed for breathing comfort and daily lung health.

Pratteln, Switzerland, 13 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Gen İlaç ve Sağlık Ürünleri San. ve Tic. A.Ş. (GEN) for the distribution and promotion of AGAMREE® (vamorolone) in Türkiye for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older.